|
|
|
Debbie Allison, M.S. Senior Director, Global Corporate Licensing Merck
Debbie Allison is Senior Director of Global Competitive Intelligence at Merck & Co., Inc. She has been with Merck for 30 years and worked in the competitive intelligence arena for over 9 years. Debbie leads the effort to ensure that Merck's competitive and strategic information systems and processes remain premier within the industry. Her responsibilities also include providing competitive intelligence to the oncology franchise.
Debbie earned a Bachelor's degree in chemistry from The College of William and Mary and a Master's degree in medicinal chemistry from The Ohio State University. Debbie joined Merck in 1979 as a Medicinal Chemist, supporting programs focused on discovery and development of anti-inflammatory agents. Debbie left the labs in the mid 1980s to lead a cross-divisional, international effort to put real-time chemical structure and reaction information at the chemist's desktop through a complete transformation of computer-based information systems. The subsequent move to the Competitive Information group was a perfect fit for Debbie's talent in assimilating data and computer systems with user's need for strategic insight.
"My passion is to utilize scientific and business information to help establish strategic direction for Merck."
_____________________________________________________________________________________________________________________________
|
|
|
|
Roland Andersson Senior Managing Director, Strategic Advisors Leerink Swann & Co
ROLAND ANDERSSON, Ph.D., has extensive experience working with biotechnology, pharmaceutical, medical device and diagnostic companies, with primary expertise in strategy, transaction support, post-merger integration and R&D strategy. Dr. Andersson has previously served as the Senior Managing Director of Leerink Swann Strategic Advisors, and built this group to become a major part of the firm. Prior to joining Leerink Swann Strategic Advisors, Dr. Andersson held positions as a Senior Partner at Strategic Decisions Group and the Global Practice Leader for Arthur D. Little Inc. Dr. Andersson started his career at Pharmacia Corporation, where he held a number of management positions in Development, Marketing and Quality Assurance. Dr. Andersson received an MS in Engineering and a Ph.D. (Teknisk Licentiat) degree in Management from Linkoping Institute of Technology (Sweden). His research work was in the area of integrated product development processes within industrial companies, and his thesis work, published as a book, is currently in the third printing.
___________________________________________________________________________________________________________
|
| |
|
Jennifer Breen Andreasson Worldwide Regulatory Policy and Intelligence Pfizer
Jennifer Breen Andreasson has over 10 years experience in the pharmaceutical industry with a focus and expertise in US, EU, and Rest of World regulatory strategy. After an internship at Pfizer’s office in Spain , she began her career at Pfizer in the Worldwide Labeling Group, where she supported the CV/Metabolic/Pain/Inflammation therapy areas. Jennifer then took an assignment with Europe/Canada Regulatory Strategy Group working on CNS/Pain/Inflammation products in Brussels , Belgium and Walton Oaks, UK . Upon completion of her expatriate assignment, Jennifer returned to the Worldwide Regulatory Strategy group in NY and supported products in the CNS therapy area. Prior to her current role as Associate Director, Competitive Intelligence, Jennifer was the Global Regulatory Lead for Viagra.
Jennifer holds a Bachelor’s degree from the University of Scranton and a certificate from the Universidad de Barcelona. She speaks Spanish, Italian, and Portuguese.
She is a member of DIA and the DIA Regulatory Affairs SIAC Intelligence Working Group.
_____________________________________________________________________________________________________________________________
|
| |
|
Jeff Beeny Manager of Corporate Strategy Thermo Fisher Scientific
Jeffrey Beeny is the Senior Manager of Business Intelligence at Thermo Fisher Scientific.
From May 2006 through November 2006, he was a key member of the Fisher Scientific anti-trust team working on the company’s $10.6 billion merger with Thermo Electron. In support of the company’s regulatory filings, Mr. Beeny managed the business intelligence process, an essential component of approval from the Federal Trade Commission (FTC) and European Commission (EC). He joined Fisher Scientific in January 2006 with the responsibility for strategic, market and competitive analysis in support of corporate initiatives and strategic decision-making.
Prior to joining Fisher Scientific, Mr. Beeny was the Principal Market Analyst, Competitive Intelligence at EMC Corporation. At EMC, Mr. Beeny was responsible for competitive and market analysis for the company’s corporate strategy focused on information lifecycle management. Prior to EMC, he was the Manager of Competitive Intelligence at Genuity, where he led competitive and strategic analysis initiatives for senior management. In the mid- to late-1990s, Mr. Beeny was a Risk Financing Analyst at Liberty Mutual and a Scientist for The Gillette Company - Duracell. He holds a B.S. General Science in Chemistry from Purdue University and earned an M.B.A. in Finance and Strategy from Boston College. Mr. Beeny has been a member of the Society of Competitive Intelligence Professionals since 2000.
_____________________________________________________________________________________________________________________________
|
| |
|
Rachid Benhamza Director Product Management Commercial Operations Helsinn Healthcare S.A.
_____________________________________________________________________________________________________________________________
|
| |
|
Eduardo Flores Bermudez (invited) Specialist for Competitive Intellignece Bayer Schering Pharma AG Chair of the Board of Directors Society of Competitive Intelligence Professionals (SCIP)
_____________________________________________________________________________________________________________________________
|
|
|
|
Stan Bernard President Bernard Associates, LLC
Stan Bernard, MD, MBA is the Founder and President of Bernard Associates (www.BernardAssociatesLLC.com), a pharmaceutical and health care industry management consulting firm that offers strategic planning, marketing, competitive simulations (war games), competitive planning, and business development services. The firm thrives on the cutting-edge: new products, technologies, services, ventures, markets, customer segments, opportunities, challenges, and issues. Bernard Associates has worked with nine of the top ten pharmaceutical companies and many of the leading biopharmaceutical, medical device, diagnostics, and health care products companies.
Dr. Bernard is nationally recognized as a health care and pharmaceutical industry consultant, speaker, and author. He has been featured on national television and in leading publications, including the Wall Street Journal, Business 2.0, and Business Week. He has published over 50 book chapters and articles on health care and pharmaceutical topics.
Previously, Dr. Bernard served as a Principal in the Health Care and Pharmaceutical Industry Consulting Practice at A.T. Kearney. Prior to joining A.T. Kearney, Dr. Bernard worked at Bristol-Myers Squibb Pharmaceutical Company where he held several executive business and medical positions. He served as U.S. Product Manager for the launch of the cholesterol-lowering drug Pravachol, Bristol-Myers Squibb’s most successful pharmaceutical product. He served as U.S. Managed Care Medical Director, the first person to hold such a position in the pharmaceutical industry, and as U.S. Director - Pharmacoeconomics. Previous positions included those in Worldwide Business Development, U.S. Medical Operations, and U.S. Medical Services.
Dr. Bernard is a former Senior Fellow in the Health Care Systems Department at The Wharton School of Business where he initiated and taught in the “Pharmaceutical Management” course for fourteen years. Dr. Bernard is the recipient of the prestigious Wharton School of Business Alumni Achievement Award for his contributions to Wharton and the health care industry. Dr. Bernard received his M.B.A. in marketing and health care management from the Wharton School of Business. He received his Medical Degree from Baylor College of Medicine.
_____________________________________________________________________________________________________________________________
|
|
|
|
Chris Bogan CEO Best Practices
Chris Bogan is the Chief Executive Officer and Founder of Best Practices®, LLC, a leader in the field of best practice performance improvement. Based in Chapel Hill, North Carolina, Best Practices®, LLC specializes in providing pharmaceutical, biotechnology and medical device corporations throughout the world with business intelligence, research, benchmarking studies, and consulting services. The company's products and services provide corporations with "Access And Intelligence For Achieving World-Class Excellence™."
Mr. Bogan received his MBA with honors from the Harvard Business School and his bachelor's degree magna cum laude from Amherst College. He was a Nieman Fellow at Harvard University. Mr. Bogan's work has focused on organizational excellence, blockbuster product launches, marketing excellence, sales force effectiveness, clinical operations and best practice improvement strategies. He has written about numerous aspects of performance excellence and continuous improvement. In recent years, he has concentrated on ways that companies can use best practice insights to create economic value, accelerate revenue and profit growth, and drive rapid performance improvement. He is co-author of the widely acclaimed books, Benchmarking For Best Practices: Winning Through Innovative Adaptation, published by McGraw-Hill, and The Baldrige: What It Is, How It's Won, and How To Use It To Improve Quality In Your Company.
Mr. Bogan has consulted on performance improvement and best practice competitiveness issues for a wide range of pharmaceutical, biotechnology and medical device companies, including Pfizer, Eli Lilly, GlaxoSmithKline, Genentech, J&J, Amylin, Sanofi-Aventis, AstraZeneca, Amgen, Novartis, Roche, Baxter Healthcare, Bayer, 3M Pharmaceuticals, Abbott Laboratories, Astellas, LifeScan, Guidant, Janssen Pharmaceutica and others.
Mr. Bogan led the consulting teams that assisted both Federal Express and GTE Directories (now Verizon) in winning the prestigious Malcolm Baldrige National Quality Award. He has also advised many leading corporations outside the healthcare sector, including industry leaders such as Microsoft, American Express, AT&T, General Motors, BellSouth, Chevron, Exxon, Xerox, Verizon, Marriott, Merrill Lynch, Siemens, KPMG, the New York Times Company, J.P. Morgan Chase & Co., TIAACREF, Nortel Networks, Pitney Bowes, Bank of America, Wachovia and many others.
A guest lecturer at Northwestern University’s Kellogg School of Management and the University of North Carolina’s (UNC) Kenan Flagler Business School, Mr. Bogan has spoken widely before business audiences in North America, Europe, Asia and Latin America. He is an advisor to various management magazines on best practice and management issues. He currently serves on the UNC Academic Leadership Institute’s National Advisory Board. Previously, he served on the Board of Directors of Ontogeny, Inc., a stem cell and functional genomics company now named Curis, Inc.
Prior to founding Best Practices, LLC, Mr. Bogan was a principal and founding member of The TQM Group, Ltd., a Bostonbased consultancy. Mr. Bogan also spent many years working at various media companies, including Times Mirror Corp., Knight-Ridder Inc., Howard Publications and Cowles Publishing Co. He has contributed articles to many newspapers and magazines, including The Harvard Business Review, Time, Pharmaceutical Executive, PharmaVoice, MedAd News, Planning Review, The Los Angeles Times, The Boston Globe, The Miami Herald, The Chicago Tribune and The Philadelphia Inquirer. Through his work, Mr. Bogan has toured manufacturing and service companies throughout the world.
_____________________________________________________________________________________________________________________________
|
| |
|
Paul Bould Head of Competitive Intelligence Bayer Healthcare
_____________________________________________________________________________________________________________________________
|
| |
|
Linda Bowen Director Regulatory Intelligence and Policy sanofi aventis
Linda is Director of Regulatory Intelligence and Policy at sanofi-aventis and has held senior regulatory affairs positions at Bayer Healthcare and Block Drug/GlaxoSmithKline, with global regulatory responsibilities for submissions, life cycle management and due diligence activities. She holds degrees in Microbiology and English from Rutgers University and an M.S. in Drug Regulatory Affairs from LIU, where she was inducted into the Rho Chi Society. She is a member of the RAPs Board of Directors, DIA, TOPRA, an editor for the 2004 RAPS publication "Fundamentals in Canadian Regulatory Affairs", Chair of the NJ/NY RAPs Chapter, past co-chair of the global briefings track (2002 & 2005 Annual RAPs Meetings) and the 1st Canadian RAPs Conference (2004), as well as a frequent speaker and author on various regulatory affairs topics. She has attained regulatory affairs certification (RAC) for the US, Canada and Europe. She is the coordinator for the DIA Regulatory Affairs SIAC and past chair of the DIA Regulatory Affairs SIAC Intelligence Working Group.
_____________________________________________________________________________________________________________________________
|
|
|
|
Branimir Brankov, M.D., M.B.A. Sr. Director Strategic Business Intelligence Merck & Co., Inc.
Dr. Branimir Brankov is a professional manager and marketer with a medical and business background and more than 15 years experience in the pharmaceutical industry.
Dr. Brankov is currently responsible for Strategic Business Intelligence Group which is part of the Global Competitive Intelligence Unit established in the Merck Headquarter in Whitehouse Station, N.J., U.S.A. In this capacity, his main functions include managing global projects and initiatives, conducting competitive analysis and providing guidance to Merck Executives and Global Marketing Teams on strategy development.
In his previous roles at Merck, Dr. Brankov has been Global Leader for Physician Communities of Practice initiative at Merck. As part of the Global market research team in Merck Headquarter he has been responsible for providing global market research and business intelligence support for several therapeutic areas. Before his assignments in Merck Headquarter Dr. Brankov was responsible for establishing and managing independent subsidiaries for Merck & Co., Inc. in Bulgaria, Macedonia and Albania.
Dr. Brankov received his M.D. from the Medical University of Sofia and practiced at the Military Medical Academy in Sofia, Bulgaria, specializing in Neurosurgery. In 2001, he obtained a Masters’ Degree in Economics from the Economics University of Sofia, with concentration in Human Resources; and, in 2003, he earned a Masters’ Degree in Business Administration from Rutgers University, New Jersey, with concentration in Marketing and Management. He is active member of PBIRG, SCIP and MRII.
_____________________________________________________________________________________________________________________________
|
|
|
|
Dr. Carole Bruckler Business Unit Director Deallus Group
_____________________________________________________________________________________________________________________________
|
| |
|
Jim Caldwell Senior Consultant Fletcher/CSI
Mr. Caldwell has more than 15 years experience in executive level financial analysis including mergers and acquisitions, business development, and P&L analysis. He has conducted numerous studies across all of Fletcher/CSI’s practice areas including working with many pharmaceutical and medical device companies in identifying M & A targets. Prior to joining Fletcher/CSI, Mr. Caldwell held several senior level positions with such organizations as Morgan Stanley, Prudential Insurance, and Cabletron Systems. Over the years, Mr. Caldwell’s experience has included heading up Investor Relations, global sales training, supply chain management, M & A identification, company divestitures, and inter-continental partner communication and coordination. Mr. Caldwell will share with you some of the knowledge he has accumulated over the years and how this information can be used to help your company identify qualified targeted M & A opportunities. _____________________________________________________________________________________________________________________________
|
|
|
|
Kurt Cannon Director Genzyme
Kurt is Director of Competitive and Technical Intelligence (CTI) at Genzyme Corp. He manages the team that provides strategic market intelligence to Genzyme’s Transplant, Oncology and Multiple Sclerosis business. In addition, Kurt heads CTI’s Science Intelligence Group and is actively involved in efforts to maximize the odds of success for Genzyme Science initiatives. Prior to Genzyme Kurt was a Pharmaceutical Market Consultant at Decision Resources Consulting, where he conducted strategic assessments such as market opportunity and optimal points of market entry for emerging therapeutics and medical devices. Kurt has scientific expertise in oncology, immunology and cell biology. He has a PhD in Cell Biology from Yale University, conducted research at Kyoto University in Japan, and was a post-doctoral Fellow of the Leukemia and Lymphoma Society at the Harvard Medical School.
_____________________________________________________________________________________________________________________________
|
| |
|
Claudio D’Ambrosio, PhD, MSc Business Unit Director Deallus Group
Claudio is Director of the Oncology Business Unit of Deallus, currently based in the City of London, but soon relocating to the USA. He has worked on many of the key oncology indications, characterized by a high degree of innovation and complexity. Claudio possesses in-depth understanding of the clinical, commercial and technological aspects associated with most of the developments in the oncology field. As well. at Deallus Claudio has been heavily involved in crafting specific analytical and modelling tools to maximize the strategic value that CI can deliver to clients.
Prior to joining Deallus, Claudio worked as post-doctoral researcher and as a PhD student at the London Research Institute of Cancer Research UK, one of the Top Ten cancer research institutes worldwide where he was described as "one face for the visionary outlook for cancer research". His PhD work was published in two top ranking peer-reviewed scientific journals. Prior to that Claudio earned a degree in Biosciences and a Masters in Biotechnology.
_____________________________________________________________________________________________________________________________
|
| |
|
Deborah Dauber Associate Director, Competitive Intelligence Genentech USA, Inc.
Deborah has been with the Genentech Competitive Intelligence group for the past five years, supporting decision making for both R&D and Commercial teams. As an individual contributor and later as the lead for the Immunology team, Deborah led competitive intelligence initiatives to investigate key competitors (product and company-level), evaluate revenue impact of competition, and assess full market landscapes. Deborah has led Competitive Intelligence at Genentech (as interim head and later as Associate Director) since 2007. Prior to joining Genentech, Deborah was a Consultant with WWMR, Inc., where she worked with clients to design and execute market/opportunity assessments and managed the analyst team on custom projects. She has a B.S. in Chemistry/Cellular and Molecular Biology from the University of Michigan, Ann Arbor, and a Ph.D. in Chemistry and Chemical Biology from the University of California, San Francisco.
_____________________________________________________________________________________________________________________________
|
|
|
|
Brett J. Davis Senior Director Oracle Health Sciences
Brett Davis is a Senior Director in Oracle's Health Sciences Global Business Unit. In this role, Brett is responsible for shaping and driving Oracle's personalized healthcare strategy and solutions. He works closely with leaders in healthcare and life sciences to help them leverage innovative information technologies and applications to innovate and grow.
In addition to his role at Oracle, he is on the Board of Directors of the Personalized Medicine Coalition, is on HRSA’s Genetic Services Policy Project Advisory Panel, is a Strategic Advisor for the Ben and Catherine Ivy Foundation for glioma research, and has been an invited speaker at industry meetings on information technology’s transformative role in the health sciences.
Prior to joining Oracle, Brett was a Business Unit Executive in IBM's Healthcare and Life Sciences business. In this role, he was involved in helping shape IBM’ s strategy for health analytics, clinical genomics, high performance scientific computing, biobanking and translational medicine.
Prior to joining IBM, Brett led business development and marketing efforts at Genstruct, Inc., a Cambridge, MA based biotech. Previously he served as Senior Product Manager and Director of Marketing for Viaken Systems, Inc., where he helped develop and market bioinformatics and knowledge management solutions for pharmaceutical research.
Brett is a graduate of The Pennsylvania State University where he was enrolled in the accelerated Science BS/MBA Program, and graduated as the Eberly College of Science Student Marshall.
Brett lives outside Philadelphia with his wife Virginia and two children, Owen and Emery.
_____________________________________________________________________________________________________________________________
|
| |
|
Jamie Denison-Pender Managing Director CIS Lifesciences
Jamie is the Managing Director of CIS Life Sciences, a global CI consultancy specializing in primary intelligence gathering, secondary due diligence, analysis and consultancy within the pharma, biotech, generics and medical device markets. Jamie joined CIS back in 1997 and prior to that was an analyst with a European strategic consultancy specializing in the energy and construction markets.
At CIS he’s been responsible for growing the business organically through a continuous enhancement of the offerings – focusing on marrying the skill sets of a traditional CI agency with those of a strategic consultancy.
Jamie has a BSc in Mechanical Engineering and Business Studies from Oxford Brookes University.
_____________________________________________________________________________________________________________________________
|
|
|
|
Richard DiCicco Chairman Harvest Moon Pharmaceuticals
Richard DiCicco co-founded Harvest Moon Pharmaceuticals by acquiring the pipeline of TCI Generics, a subsidiary of the renowned Technology Catalysts founded by Mr. DiCicco in 1979. Harvest Moon Pharma develops high barrier to entry generic drugs and biosimilars. Currently there are 35 P-IV ANDA products in the Harvest Moon Pharma pipeline. In biosimilars, Harvest Moon Pharma is commercializing EPO-alpha, beta-interferon 1a and 1b, peginterferon alfa-2b, imiglucerase, filgrastim, pegfilgrastim, r-hu-insulin, glargine, lispro, etanercept, trastuzumab, rituxumab, bevacizumab, cetuximab and adalimumab). Mr. DiCicco is a member of the Editorial Board of the Journal of Generic Medicines, a member of the Licensing Executives Society, and is widely published in generics and biosimilars. ___________________________________________________________________________________
|
|
|
|
Sandipa Dublish Director, Global Market Research Eisai
Sandipa Dublish is Director, Global Market Research at Eisai Corp. In this role she manages all aspects of strategic business insights including Competitive Intelligence. In her previous position as Director, Oncology Market Research with Bristol-Myers Squibb – Sandipa was an active user of Competitive Intelligence. She therefore has a unique perspective on CI both as a provider and a user.
Sandipa holds a PhD. in Marketing from Florida International University and an MBA from Faculty of Management Studies, Delhi, India.
_____________________________________________________________________________________________________________________________
|
|
|
|
Mark Edelstein Senior Director, Market Research Lundbeck
Mark Edelstein has been an active champion for the Marketing Research function for nearly 25 years, committed to, and passionate about raising the standards, excellence and impact of this remarkable function. Currently, Mark is Senior Director of Marketing Research for Lundbeck Inc., in the Chicago metro area, the U.S. affiliate of this Copenhagen-based pharmaceutical company. Prior to joining Lundbeck, Mark spent nearly 9 years as a global pharmaceutical marketing research consultant. From 2008-2009, he was Vice President, Marketing Research for the new U.S. subsidiary of the Planning Shop international – a UK based pharmaceutical marketing research consultancy. In 2001, Mark founded his own company, Mark Edelstein Consulting, Inc., where he served as President and lead consultant to the global healthcare industry, focusing on cultivating Marketing Research and Business Intelligence. Prior to starting up his own consulting firm, he spent 15 years on the healthcare manufacturer ("client") side, working for such Pharmaceutical leaders as Pharmacia, Abbott Laboratories, Searle (Monsanto), and Merck & Co. Over that time, Mark was the lead market researcher driving the development and launches of some of the industry’s most successful products, including Prilosec™, Biaxin™, Depakote™, and Celebrex™. Under his leadership, Marketing Research has brought marketing insight and perspective to guide many other products in pre-clinical, launch and mature life-cycle stages.
Mr. Edelstein’s approach as a Research Consultant has always been to lead with vision, creativity, and a passion for excellence. Mark is a strong proponent of “Knowledge Integration”: (1) probing to understand the full scope / constraints of the business issues and decisions to address; (2) “mining” the existing body of data available from primary, secondary, syndicated research and “human capital” resources; (3) looking for synergies and gaps; (4) proposing customized solutions.
Building on that foundation, one of Mark’s passions is to build a Competitive Intelligence function and expertise to complement Marketing Research for even more comprehensive, proactive and strategic insights into our current and future markets and competitors.
Recently, Mr. Edelstein completed a 4 year term as a mentor-coach for students enrolled in an online certification program for marketing researchers worldwide: Principles of Pharmaceutical Marketing Research – sponsored by the University of Georgia. He was very excited to be a part of this revolutionary new course, and excited to work together with new colleagues from around the globe.
Among Mark’s professional affiliations, he is proud to be an active member of the American Marketing Association, the Pharmaceutical Market Research Group (for which he has served as Vice President, Treasurer, Board Member, Program Chair, Facilitator, and Speaker over the past 20 years), the PharMarketing Research Conference (serving as co-chair at the first annual meeting in 20`0), as well as being an active participant with the Pharmaceutical Business & Intelligence Research Group, the Pharma CI Conference and the Society of Competitive Intelligence Professionals.
Mark began his professional career as a practicing Chemical Engineer for nearly 10 years, crediting his experiences at FMC and Procter & Gamble with teaching him the art and skill of problem solving, project management, and the critical importance of collaborative work relationships. He holds a Bachelor’s Degree in Chemical Engineering from Lehigh University in Bethlehem, Pennsylvania, and a Master’s Degree in Marketing from Drexel University, Philadelphia, Pennsylvania.
_____________________________________________________________________________________________________________________________
|
|
|
|
Beth Elliott Vice President, Healthcare, Europe Fuld & Co.
Beth Elliott is the Vice President of Fuld & Company’s European Healthcare Practice and has ten years experience in CI. She started her career as a Research Analyst and has run over 200 projects within the Pharmaceuticals and Biotech sectors focusing across the value chain. Beth has also trained over 150 people on how to illicit and protect information within congress settings.
_____________________________________________________________________________________________________________________________
|
|
|
|
Laura Farmer Executive Vice President The Larvol Group
Laura Farmer is the Executive Vice President for The Larvol Group. Over the past 17 years, she has led a wide range of strategy, marketing and commercialization projects within the biopharmaceutical industry. Through her work, Ms. Farmer has developed expertise across numerous functional groups and therapeutic areas including oncology, rheumatoid arthritis, and CNS.
Ms. Farmer was a contributing author of Forces Reshaping the Performance and Contribution of the U.S. Medical Products Industry, an in-depth industry outlook, prepared for the Health Industry Manufacturers Association and presented to Congress, which helped precipitate regulatory reform for devices.
Before working with The Larvol Group, Ms. Farmer consulted and led projects with Straticore, Publicis Healthcare, Insight Strategy Advisors, True North Partners, CSC Healthcare, and The Wilkerson Group for top pharmaceutical and biotech firms. She received a Bachelor of Arts cum laude in Political Science with distinction and Pre-Medical studies from Yale University.
_____________________________________________________________________________________________________________________________
|
|
|
|
Neelima Firth Vice President, Healthcare Markets Fletcher/CSI Healthcare Strategies
Neelima Firth is an experienced biopharmaceutical executive with extensive scientific, reimbursement, marketing and international experience in start up and Fortune 500 biopharmaceutical companies including GSK, Bristol Myers Squibb, Sandoz and Amgen. As VP Healthcare Markets at Fletcher/CSI Healthcare Strategies, Neelima influences strategic and tactical direction for Fletcher/CSI’s Managed Markets and General Healthcare practices. Working closely with clients in the pharmaceutical and payer environments, Neelima is integral in designing and implementing effective competitive client market penetration programs.
Previously, she was the Director of Strategic Planning and Operations at Amgen and led the strategic planning and operations group and worked closely with the competitive intelligence group in gathering critical business information to aid informed decision making.
She worked at Amgen for 16 years in a series of increasingly senior roles in clinical, marketing and reimbursement in the UK and USA. Accomplishments includes developing compendia strategy, managing Medicare and Medicaid marketing strategies, creating alliance management governance and managing clear brand planning processes. She was instrumental in building the initial UK/European presence of Amgen to support the launch of new products. In England, she was the President of AIOPI- Association of Information Officers in the Pharmaceutical Industry. She is a board member of the Association for Strategic Planning in LA.
She has an Information Science degree from Leeds Metropolitan University in England, a Certificate in Legal Studies from Cambridge University in England and an MBA from Pepperdine University in the US.
_____________________________________________________________________________________________________________________________
|
|
|
|
Carolyn J. Foster Sr. Associate Director, Technology Assessment Boehringer Ingelheim Pharmaceuticals, Inc.
Dr. Foster joined Boehringer Ingelheim Pharmaceuticals in 2001 and now heads the Competitive Technical Intelligence group for cardiovascular and autoimmune diseases. In that capacity, she analyzes the external environment in the context of internal business issues, especially where technology is a factor. Her internal clients include R&D, Marketing and Medical management and the analysts that support them.
Prior to her CTI career, Dr Foster spent 20 years as a biochemical pharmacologist in Cardiovascular Drug Discovery at Schering Plough working on drugs to treat hypertension, atherosclerosis, thrombosis, and Parkinson’s Disease. Her published research focuses on G-protein coupled receptors and platelet function.
Dr. Foster studied chemistry at Swarthmore College, received an M.S. in biochemistry from Brown University and a Ph.D. in pharmacology from the University of Medicine and Dentistry of New Jersey. She did post-doctoral research at the University of Pennsylvania in human genetics. She is a Fellow of the New York Academy of Sciences where she has served as a member the conference planning committee, as Chair of the Biochemistry Section, and as head of the Biochemical Pharmacology Discussion Group, an academia-industry consortium.
_____________________________________________________________________________________________________________________________
|
| |
|
Sean D. Freston Managing Director, Asia Pacific Proactive Worldwide
Sean Freston is the Managing Director, Asia-Pacific for Proactive Worldwide.
Sean has 15 years of experience living in and conducting business with China and the Asia-Pacific region. Over the past three years he has been based in Shanghai tasked with business development in Asia for a global CRO. In his previous role with Proactive Worldwide, Sean led the pharmaceuticals practice in conducting domestic and international competitive intelligence engagements. Over the course of five years, he was intimately involved with decision support projects across multiple therapeutic areas from early discovery through marketing/lifecycle management initiatives.
He holds an MBA from Thunderbird School of Global Management, Arizona, and a BA from the University of Puget Sound, Washington.
_____________________________________________________________________________________________________________________________
|
|
|
|
FELIX W. FRUEH, Ph.D. Vice President, Research and Development, Personalized Medicine Medco Health Solutions, Inc.
Dr. Felix Frueh joined Medco in May 2008 to lead Medco’s personalized medicine research and development organization. In this function, Dr. Frueh manages Medco’s expanding research efforts in personalized medicine, leveraging the newest developments in science to improve the safety and efficacy of prescription drug care. He is also responsible for the development of Medco’s Personalized Medicine Research Center, which is under construction in Whitestown, Indiana.
Prior to joining Medco, Dr. Frueh was Associate Director for Genomics at the U.S. Food and Drug Administration (FDA), where he built and led a core genomics review team in the Center for Drug Evaluation and Research (CDER), and chaired the first FDA-wide, interdisciplinary pharmacogenomics review group (IPRG). Prior to the FDA, he was Managing Partner at Stepoutside Consulting, LLC, and held senior positions at Transgenomic and Protogene Laboratories.
Dr. Frueh’s academic career includes a faculty appointment at the Departments of Pharmacology and Medicine at Georgetown University in Washington DC, and postdoctoral fellowships at Stanford University and the University of Basel, Switzerland, where he also received his Ph.D. in biochemistry. _____________________________________________________________________________________________________________________________
|
| |
|
Kazumi Fujikawa Director, Market Research Pfizer, Japan
_____________________________________________________________________________________________________________________________
|
|
|
|
Tom Fussaro Director, Government Relations and Public Policy Millennium: The Takeda Oncology Company
Tom Fussaro acts as Director, Government Relations and Public Policy at Millennium: The Takeda Oncology Company. In his current role, Tom is responsible for analyzing and responding to developments in federal and state government policy affecting Millennium and the biopharmaceutical industry – including health care reform, comparative effectiveness research, PDUFA reauthorization and the creation of a regulatory pathway for the approval of biosimilars. Prior to joining Millennium, Tom served as senior legislative assistant and health care policy advisor to Congressman Mike Ferguson (R-NJ, retired). While working on Capitol Hill, Tom assisted Congressman Ferguson in his work on the House Energy & Commerce Committee during consideration of legislation such as the Medicare Modernization Act, the Deficit Reduction Act of 2005 and PDUFA IV. Tom graduated from Wake Forest University with a Bachelor of Science in Business and is currently pursuing a Master of Business Administration at the University of Chicago .
_____________________________________________________________________________________________________________________________
|
|
|
|
Dr. Benjamin Gilad Owner Academy of Competitive Intelligence
Ben Gilad wrote the book on war games (literally, in 2009, Business War Games, Career Press). Since 1991, Ben has been running war games for the Fortunate 500, and training corporate managers in the art of predicting competitors’ moves. Most don’t listen to him, but they keep coming back calling his blunt style refreshing. You can find more about him – but ask yourself why you want to know more first - at www.GiladWarGames.com and www.academyci.com. In his past he was a good strategy professor (Rutgers U), a lousy junior police intelligence officer (Israel), and an old fashioned, free market economist (Ph.D 1981, NYU). He still misses his undergrad classes at Rutgers who believed every word he said. He does not miss the MBA classes, though. He lives with his family in Boca Raton, FL where he is the only one on his block who does not drive a Mercedes.
_____________________________________________________________________________________________________________________________
|
| |
|
Erik Glitman Managing Director Fletcher/CSI
Erik Glitman is a founder and Managing Director of Fletcher/CSI and serves as the Director of Global Operations, Research, and Strategy. As a founder of Fletcher/CSI, he has been active in the Competitive Intelligence industry for over 15 years. He has worked with clients in areas such as automotive, electronics, Healthcare, IT, kitchenware, machinery, pharmaceuticals, and Telco.
As an active part of the Fletcher/CSI consulting practice, Erik has extensive experience in working with clients to help them gain competitive advantage in the marketplace through the integration of qualitative and quantitative CI collected from global sources. Fletcher/CSI, headquartered in Williston, VT, has been active in the international CI marketplace since its inception and operates with 22 affiliate offices world-side. International clients use Fletcher/CSI consulting services to understand competitor positions and develop strategies to increase profitability. A global leader in ethical CI, Fletcher/CSI has a history of accurate and timely analysis on competitive situations while working with clients to develop effective strategies in rapidly changing markets.
Erik holds a B.S. degree in Economics from the University of Vermont, a B.S. in Environmental Studies from Johnson State College, and an M.S. in International Affairs from American University. He is active with local charities and serves on the board of the Vermont Multiple Sclerosis Society Bike Tour, to be held in August of each year.
_____________________________________________________________________________________________________________________________
|
| |
|
Thomas Han Vice President US Marketing Biovail
Mr. Han has over sixteen years of successful pharmaceutical industry experience including in-depth experience within strategic marketing, pre-launch commercialization, product launches, brand marketing and field sales.
Mr. Han started his pharmaceutical career in field sales and was successfully promoted to positions within sales operations and marketing at Bristol-Myers Squibb. He then moved into marketing roles at both Novartis and Schering-Plough. Mr. Han has had the opportunity to hold leadership roles on both small and blockbuster brands.
In his current role, he is responsible for leading the product candidate identification and commercial assessment process for Biovail. This includes forecast development and market research to validate and quantify the risks associated with each opportunity across multiple therapeutic areas.
_____________________________________________________________________________________________________________________________
|
| |
|
Michael Heerde Director Strategy & BD Bayer Schering Pharma China
_____________________________________________________________________________________________________________________________
|
| |
|
Chris Hote President Digimind
Chris Hote is President of Digimind Inc. In his role, Hote works with organizations of all kinds to develop their intelligence framework to monitor, detect and interpret change in their business environment. Hote also defines the strategy for easing adoption of competitive intelligence products throughout the CI community.
Hote joined the Society of Competitive Intelligence Professionals in 2008 and participates in SCIP New England chapter. Previous to joining the Digimind company Hote participated in multiple high-technology companies. Lastly, Hote co-founded the PolySpace start-up company focusing on the embedded software market that got acquired by The MathWorks: a great experience to understand the role of competitive intelligence as an executive practitioner. Hote has a PhD in physics, an MBA from Toulouse university and is a fellow student from MIT Sloan.
_____________________________________________________________________________________________________________________________
|
| |
|
Margaret Hsiao CEO & Co-Founder Harvest Moon Pharmaceuticals
Margaret Hsiao has over 20 years of technical and commercial experience in the Rx and OTC pharmaceutical industry for both the branded and generic drug space. Harvest Moon Pharma product focus include biosimilars, high barrier to entry pharmaceuticals, and drug products for the emerging markets.
_____________________________________________________________________________________________________________________________
|
| |
|
Philip Lin Huang Executive Director Merck & Co Inc.
_____________________________________________________________________________________________________________________________
|
|
|
|
Colonel Ray S. Jeter Chief, AFMS Innovations Deputy Chief Medical Information Officer Air Force Medical Systems
Colonel Jeter was born in Stuttgart, Germany. He received his Bachelor of Science in Biology from The Citadel in 1983 and his Doctorate of Medical Dentistry from The Medical University of South Carolina in 1987.
As Chief of Innovations for the Air Force Medical Health System he interacts with DoD, government and academia identifying and exploring novel concepts, new processes and disruptive technologies that have the potential to dramatically transform Air Force Medical Service capabilities. His office provides strategic discovery and initial analysis of novel concepts. He tracks initiatives and translates them upon maturation to tactical AFMS requirements. Col Jeter, as the senior dental subject matter expert at the Air Force Medical Support Agency provides functional expertise in the development of the MHS Electronic Health Record Way Ahead and functions as the AFMS Deputy Chief Medical Information Officer.
He completed his Advanced Education in General Dentistry in 1996 and became a Diplomate of the Federal Services Board of General Dentistry in 1998. Col Jeter is presently board certified by the American Board of General Dentistry. He practices comprehensive dentistry regularly at Bolling AFB and the Pentagon Tri-Service Dental Clinic.
Col Jeter is married to Carol Joyce Fanning of Charleston, South Carolina. They have two children, Britton (18) and Claire (14).
_____________________________________________________________________________________________________________________________
|
|
|
|
Derek L. Johnson CEO Aurora WDC
Derek Johnson is Chief Executive Officer of Aurora WDC, a competitive and market intelligence firm founded in 1995 that works within all sectors including CPG, Financial Services, Life Sciences, and Technology & Telecommunications. In addition to setting the strategy of the firm and being very involved in client management and new business development, he is responsible for oversight of all client research and analysis engagements in terms of overall quality control and calendar-based project management. Working with the firm’s senior research leaders, he carefully guides the process by which Aurora scopes all research engagements in terms of project design and methodology, while also managing any conflict-of-interest issues and the client relationship overall. Derek’s academic achievements include an MBA from the University of Wisconsin – Madison and a BBA in Finance and Economics from the University of Wisconsin – Eau Claire. He was awarded SCIP’s Catalyst Award in 2010, served as Wisconsin’s SCIP chapter co-chair from 2007-2009, Program Chair of the 2009 SCIP International Conference, and is also a Chartered Financial Analyst (CFA).
_____________________________________________________________________________________________________________________________
|
|
|
|
Cliff Kalb President C. Kalb & Associates
Clifford Kalb currently serves as Vice President, Life Sciences at Wood Mackenzie, Inc. In this capacity he provides thought leadership on industry issues and supports their knowledge based research and consulting practice.
Mr. Kalb has over thirty five years of experience in the pharmaceutical industry. Previously, he served as Senior Director, Strategic Business Analysis, in Worldwide Human Health Marketing at Merck & Co., Inc. Prior to that, he held positions of increasing responsibility in sales, market research, health economics, public policy management, marketing management, licensing, business intelligence and business development at Marion Labs, Pfizer and Roche. He has also served as head of marketing and business development for a small biotechnology company.
Mr. Kalb has served as Chairman of the Conference Board Council on Competitive Analysis. He is also Past President of the board of directors of the Society of Competitive Intelligence Professionals (SCIP), and Past President of the Pharmaceutical Business Intelligence and Research Group (PBIRG). Mr. Kalb is widely published in the field of pharmaceutical industry intelligence and analysis.
In 2004, he was made a Fellow in SCIP, and received the Lifetime Achievement Award from PBIRG. In 2005, he was named one of top 100 most inspiring people in the pharmaceutical industry by Pharmavoice magazine. Mr. Kalb holds a Bachelor’s degree in Biology and Psychology from Rutgers University, and an MBA in Pharmaceutical Marketing and Economics from Fairleigh Dickinson University.
_____________________________________________________________________________________________________________________________
|
| |
|
Gerald Kunze Associate Director, Market Research & Business Analytics CSL Behring
Gerald Kunze is the Associate Director of Market Research & Business Analytics for CSL Behring, a $4 billion biopharmaceutical firm specializing in plasma products and flu vaccines. His principle responsibilities include management of competitive intelligence, business analytics and market research for the entire U.S. operation. Mr. Kunze’s group supports decision-making for the full range of businesses within CSL including immunology, bleeding disorders and other rare diseases.
In addition to the functions he currently supports, Mr Kunze’s work experience spans a range of functional areas including marketing & sales, corporate planning, finance, engineering and manufacturing.
Prior to his career in pharmaceuticals, he worked as a business consultant and corporate planner in the environmental and chemical industry.
Mr. Kunze formerly served as an adjunct professor of business in the Penn State system.
He earned his BSE in Chemical Engineering from Princeton University and a MBA from the University of Pittsburgh.
_____________________________________________________________________________________________________________________________
|
|
|
|
Susan Laufer Director, Strategic Research ImClone Systems Corp, a wholly-owned subsidiary of Eli Lilly & Co.
Susan Laufer, MS, is Director, Regulatory Strategic Research at ImClone Systems, a wholly owned subsidiary of Eli Lilly & Co., where she is in the process of creating a new regulatory intelligence function. Prior to joining ImClone, Ms. Laufer was a member of sanofi-aventis’ Regulatory Intelligence team, where she was responsible for covering oncology. Ms. Laufer began her career in Pharma 25+ years ago as an analytical R&D chemist with Teva Pharmaceuticals in Israel, later moving to QA as a technical writer and then internal auditor, conducting internal GMP and ISO 9000 audits in four plants that manufacture and package a variety of parenteral, liquid, and solid dosage products. Upon returning to the U.S. she established and implemented a GMP/CE quality system for Light Age, Inc., a medical and scientific laser manufacturer, where as their first head of Regulatory Affairs she had full responsibility for regulatory compliance and submissions, QA activities, SOP writing and training, and documentation control. Ms. Laufer holds a Masters degree in chemistry from Israel’s Weizmann Institute of Science and a BA in both chemistry and biochemistry from Brandeis University, magna cum laude with honors in chemistry. She is also a proud graduate of the Bronx High School of Science in New York.
_____________________________________________________________________________________________________________________________
|
|
|
|
Mark Little Vice President, Business Intelligence & Market Research Covance, Inc.
Mark is currently Vice President, Business Intelligence at Covance Inc. in Princeton NJ. Mark joined Covance in 2002, and has since merged the intelligence function with the market research function to form a more comprehensive, external-focusing unit at Covance. Before joining Covance, Mark worked in the pharmaceutical industry with Glaxo, where he led a business-driven competitor intelligence operation that effected decisions related to both R&D and commercial strategies.
Mark received a BS in chemistry from the University of North Carolina and a Ph.D. in biochemistry from The Ohio State University. Following his doctorate, Mark received a National Science Foundation fellowship to conduct research at the University of Grenoble, in France.
Mark has been active with the Society of Competitive Intelligence (CI) Professionals, or SCIP, the 5000-membered organization for CI. Mark served as SCIP President in 2001-2002, and as a Board member, 1998-2003, and is currently a member of the SCIP Education Committee. Mark is also a member of the Intelligence Leadership Forum, a thought-leading intelligence organization established in 2003.
Mark has given frequent presentations on CI at conferences and business schools, and has authored several articles on the subject.
_____________________________________________________________________________________________________________________________
|
|
|
|
Dr Anna Mandinova Professor Harvard Medical School
Anna Mandinova is Professor at Harvard Medical School and Associate Member of the Broad institute of Harvard and MIT. Dr. Mandinova possesses considerable experience in systematic small molecule technologies and their implication for cancer therapy. Her significant experience in this area has played a major role in the development of a Chemical Genetics Core facility at the Massachusetts General Hospital, which she is currently directing.
Dr. Mandinova received her M.D. from the Medical University in Sofia, Bulgaria. She earned a Ph.D. in Cell Biology as part of the M.D./Ph.D. Program at the University of Basel, Switzerland. Later, Anna Mandinova joined the laboratory of Dr. T. Maciag in the Center for Molecular Medicine at Maine Medical Center Research Institute in Scarborough. As a research fellow in this lab, Dr. Mandinova was the first to demonstrate that IL-1a, similarly to FGF-1 is exported from cells as a component of a multiprotein release complex in a stress-induced and copper-dependent manner. Her in vitro data served as a basis for clinical studies pioneered by Dr. S. Marajver’s lab in which this approach was used to manage the progress of stage IV tumors in patients.
Anna Mandinova’s long-term goal as a physician scientist is to promote a translational research effort at Harvard medical School integrating the efforts of a multidisciplinary team for drug development in the field of epithelial cancers.
_____________________________________________________________________________________________________________________________
|
| |
|
Michael Martinolich Vice President and Senior Consultant Fletcher/CSI Healthcare Strategies
Mr. Martinolich is the Vice President and Senior Consultant at Fletcher/CSI Healthcare Strategies. He is responsible for leading the company’s management consulting services for their pharmaceutical and biotech clients. He is an accomplished veteran of the pharmaceutical industry with over 30 years of experience in many functional areas within pharmaceutical companies.
His expertise includes all levels of sales, sales training, marketing management, business development, business operations, as well as strategic and competitive insight. He has worked at the local, national and global levels and has been instrumental in pioneering many innovative programs, including development of commercialization strategies, implementation and management that have been responsible for revenue growth globally.
___________________________________________________________________________________________________________
|
|
|
|
Liz Mathews Principal MedPredict
Liz has an extensive background in pharmaceutical marketing and competitive analysis. Prior to co-founding MedPredict, Liz worked as an independent marketing consultant, completing numerous strategic marketing, business development, training and competitive intelligence projects for top tier pharmaceutical clients, as well as clients outside the healthcare industry. Liz spent the first decade of her career in brand management with Procter & Gamble, where she led strategic planning and marketing programs for pharmaceutical brands in all phases of their life cycles and in multiple therapeutic areas.
Liz has an MBA from the University of Cincinnati College of Business and a BA from Siena College.
_____________________________________________________________________________________________________________________________
|
|
|
|
Dr. Martha Matteo Corporate Advisory Board, BioXcel Fellow (2010) and past President, SCIP Former Director, Knowledge Management and R&D Planning, Boehringer Ingelheim
Dr. Matteo founded the Competitive Technical Intelligence (CTI) function at Boehringer Ingelheim Pharmaceuticals, Inc. in 1988 and responded to a board request to help globalize it two years later. The function continues today, ever-adapting to the evolving needs of corporate decision-makers and those who support them.
A biochemist by training and profession, Dr. Matteo developed the “CI perspective” through the Society of Competitive Intelligence Professionals (SCIP). An active member since 1989, she served on the board of directors (2005-2008), as Vice President and President (2007). She has spoken at local and international meetings, co-chaired two international CTI meetings and sponsored four academic interns from the University of Missouri at Kansas City, in collaboration with Professor Patrick Bryant. Dr. Matteo has authored articles on CTI for Competitive Intelligence Review, Competitive Intelligence Magazine (SCIP), Research and Technology Management (Industrial Research Institute) and two recent SCIP publications (Starting a CI Function and Competitive Technical Intelligence). She was honored by SCIP (Catalyst Award, 2006; Fellow, 2010) and Frost & Sullivan (Lifetime Achievement in CI, 2007) for her contributions to the field.
Dr. Matteo also remains active in the New York Academy of Sciences, where she meets regularly with pharma colleagues from industry and academia. At the Academy, she chaired the Biochemistry Section and the Biochemical Pharmacology Discussion Group, served on the board of directors and was elected a Fellow.
Dr. Matteo has a PhD in biochemistry from Brandeis University and was a founding faculty member of the University of Massachusetts/Boston. After an academic career, she transitioned to applied research in industry, first at Union Carbide and then at Boehringer Ingelheim, where, after 8 years in the lab, she moved into CTI. Dr. Matteo retired from Boehringer Ingelheim in 2006 as Director of Knowledge Management and R&D Planning. She remains active in SCIP and the field of CTI, lecturing, writing and mentoring scientists and CI groups interested in CTI.
___________________________________________________________________________________________________________
|
|
|
|
Craig McHenry Director, Competitive Intelligence, Market Analytics, Specialty Care Business Unit Pfizer Inc.
_____________________________________________________________________________________________________________________________
|
| |
|
Gretchen Moss Senior Manager, Business Services Merial
Gretchen Moss is the Senior Manager, Strategy and Business Development at Merial. Over the past 15 years she has led competitive intelligence, business development, and marketing projects across a range of industries and geographies. Gretchen entered the world of veterinary medicine in 2005 as the Associate Product Manager for Frontline, one of the largest brands in the animal health care industry. After achieving record Frontline market share and dispensing, she quickly rose to her current role at Merial. She has a BA in Economics from Mount Holyoke College in Massachusetts and a MBA in Marketing and Operations Management from Carnegie Mellon University's Tepper School of Business. _____________________________________________________________________________________________________________________________
|
|
|
|
Shacker Mourad, R.Ph, MBA Founding President NOAHSPHARM
Shacker is a consulting Health Care Professional and Practicing Pharmacist in a teaching hospital setting in the United States. He founded NOAHSPHARM upon leaving AstraZeneca in 2008. Shacker’s 28-year pharmaceutical career spans the value chain in the US and abroad, where he worked for Eli Lilly, Schering Plough, and AstraZeneca. He had held positions of increasing responsibilities in clinical development and sales and marketing, including the Director of Competitive Intelligence.
Shacker holds an Executive MBA degree in Pharmaceutical Marketing from ST. Joseph’s University and Pharmacy Licenses in Pennsylvania and New York. He is currently a graduate student of health policy at the Mayes College of Healthcare Business and Policy, at the University of the Sciences in Philadelphia.
_____________________________________________________________________________________________________________________________
|
|
|
|
Marjorie Norman Director, Worldwide Competitive Intelligence Pfizer
Marjorie G. Norman is Director, Worldwide Copetitive Intelligence for Pfizer, specializing in providing business and competitive intelligence to senior R&D management. Prior to joining Pfizer in 2002, she was Director – Pharmaceutical Practice, at Fuld & Company, a competitive intelligence consulting firm and a Senior Market Research Analyst at Johnson & Johnson Professional. Ms. Norman holds an MBA from the Graduate School of Management at Simmons College and a BA in German and art history from Franklin & Marshall College. She recently returned from a six-month deployment at Population Services International in Nairobi, Kenya, as part of the Pfizer Global Health Fellows program.
_____________________________________________________________________________________________________________________________
|
|
|
|
James (JJ) Owen, Ph.D. Director, Scientific & Competitor Analysis Millennium Pharmaceuticals
With over 6 years of experience in the competitive intelligence field, JJ is an Associate Director leading the Scientific & Competitive Analysis group at Millennium Pharmaceuticals in Cambridge , MA . The group’s responsibilities include the monitoring of competition from R&D through Commercial and working on cross-functional initiatives within the company.
Previously, JJ spent several years as an analyst within Business Development at AVEO Pharmaceuticals assisting with market research, public relations, licensing partnerships and R&D collaborations. Other work experience include a stint with a Knowledge Management function at Millennium Pharmaceuticals and managing teams of curators/editors while at Proteome/Incyte Genomics. JJ holds a B.S in Microbiology from Mississippi State University and a Ph.D. in Cell Biology from Vanderbilt University .
_____________________________________________________________________________________________________________________________
|
|
|
|
Valerie Pajak Glyptis Senior Manager, Business Intelligence & Analytics APP Pharmaceuticals
_____________________________________________________________________________________________________________________________
|
|
|
|
Daniel Pascheles Vice President, Head Global Competitive Intelligence Merck & Co.
Dr. Daniel R. Pascheles is Vice President, Global Competitive Intelligence, and is based in Whitehouse Station NJ, at the Global HQ of Merck & Co., Inc.
His responsibilities include providing intelligence regarding business, research and development activities of competitors, as well as participating in, and contribution to the strategy development process, the target identification for licensing and M&A activities.
Pascheles joined Merck & Co., Inc. early 2005 from Aventis Inc. where he was Vice President and head of Corporate Competitive Intelligence. He has worked for Aventis and its predecessor company (Hoechst Marion Roussel, Marion Merrell Dow) for 14 years in various positions and locations.
Pascheles studied Pharmacy at the Swiss Federal Institute of Technology in Zurich, Switzerland. He received his Ph.D. in Pharmaceutical Technology from the same university. He has done additional study at the University of Kansas in Lawrence, Kansas.
Pascheles is Past-President and current Board member of the Pharmaceutical Business Intelligence & Research Group (PBIRG). He is also member of the Society of Competitive Intelligence Professionals (SCIP) and the Licensing Executive Society (LES).
_____________________________________________________________________________________________________________________________
|
|
|
|
Christopher Perkins Head of Global Competitive Intelligence Roche Diagnostics - Diabetes Care
Christopher Perkins currently manages the Business Intelligence function for Roche Diabetes Care. Mr. Perkins has a BA (Hamilton College) and an MA (Penn. State) in Mathematics.
Before coming to Roche, Mr. Perkins worked as a Market Research Manager in IBM’s PC Division. Prior to his current role at Roche, Mr. Perkins was Manager of Market Research and also held an international assignment in Switzerland as Head of Market Insight and Analysis for Roche’s Insulin Pump business.
Mr. Perkins has had the opportunity to sit on the American Marketing Association’s Advanced Research Techniques program committee and has published in the SIAM Journal of Numerical Analysis.
_____________________________________________________________________________________________________________________________
|
| |
|
Roslyn Potter Research Fellow Vertex Pharmaceuticals Inc
Twenty-nine years experience in pharmaceutical research, including nineteen years in scientific intelligence.
Vertex Pharmaceuticals, January 2009 to the present, providing scientific intelligence for preclinical and clinical teams. Also provides answers to scientific questions in early research.
- Evaluation of the competitor landscape
- Target identification and target validity for early research
- Providing input to the research review committees
- Prediction of development risks of Vertex and competitor companies and suggestions for optimization for Vertex
DSM Pharmaceutical Products, 2004-2008: Scientific Intelligence used to identify top products for Sales Force
Consulting: Independent consulting to Pharma for preclinical projects. Also worked with consulting firms such as Fuld, and the Dunn Group
Hoffmann La Roche, 1981-1998: Started Scientific Intelligence in its current form in 1991
- Performed special projects for upper management
- Provided scientific intelligence to preclinical R&D
- Providing input into research review committees
- As part of preclinical R&D created Research Updates Online, an internal, interactive database containing hard and soft information derived from
external commercial databases, as well as from internal contributors
- Database was used by preclinical, clinical, patent law, M&A, and business development
_____________________________________________________________________________________________________________________________
|
| |
|
Pablo Prados Senior Director Scientific Competitive Intelligence Sanofi-Aventis
Pablo Prados is Head, Senior Director of Scientific Competitive Intelligence at sanofi-aventis. Pablo holds PhDs in Pharmaceutical Sciences from the University Complutense of Madrid and the University of Tokyo, and received his MBA from Temple University. Pablo worked in Japan for 10 years in the Pharma industry, holding positions in both R&D and Pharma Operations, such as Regulatory Affairs Manager with Nippon Schering, Strategic Planning Director with Nippon Roche, New Products & Opportunities Head with Aventis Japan, and Business Analysis Head with sanofi-aventis Japan, before moving to Paris in June 2007 to his current position.
_____________________________________________________________________________________________________________________________
|
|
|
|
John Rafa Senior Manager, Business Intelligence Covance
John Rafa currently holds the position of Senior Manager, Business Intelligence at Covance, a leading drug development services provider based in Princeton, New Jersey . Mr. Rafa joined Covance in August 2006 and supports strategic planning, corporate development and marketing initiatives throughout the organization. Mr. Rafa’s experience includes three years as an analyst for Strategic Business Research, providing consulting and market research services to biopharmaceutical companies, and several years as a consultant for BearingPoint, where he delivered information systems solutions and management consulting to Fortune 500 clients. His education includes a BS in Marketing from Villanova University and an MBA from Temple University .
_____________________________________________________________________________________________________________________________
|
|
|
|
Chandra Ramanathan Director, Commercial Development Oncology Bayer HealthCare Pharmaceuticals
Dr. Chandra Ramanathan has been associated with pharmacy academia and pharmaceutical industry for more than 22 years. He has successfully applied scientific insights to address business issues in oncology, immunology, Neuroscience and gastroenterology. He has extensive experience in Identifying new licensing/business development opportunities and conducting scientific and commercial due diligence on both compounds and technology deals.
Dr. Ramanathan has contributed to the launch of Orencia (Biologic; Rheumatoid arthritis) and Sprycel (small molecule; Chronic Myelogenous Leukemia) by incorporating competitive insights in marketing strategy development and execution. He has worked across the product development and commercialization spectrum from discovery, clinical development to marketing. He has successfully worked in new product planning/product commercialization and has contributed to the development of clinical and commercial strategy for early and late-stage compounds. He also played a key role in evaluating biosimilars for potential opportunities and assessing risk for the commercial franchise.
_____________________________________________________________________________________________________________________________
|
|
|
|
Bobbi Sue Richardson V.P. Institutional Sales Sagient Research Systems
Bobbi Sue Richardson is Vice President of Institutional Sales at BioMedTracker. Bobbi Sue joined Sagient Research Systems over 13 years ago and was V.P. of Institutional Sales for Sagient's product, PlacementTracker, and applied her sales experience into the healthcare industry. Bobbi Sue is responsible for the growing BioMedTracker business in the pharmaceutical, biotech industry and financial industries, as well as managing client relationships.
BioMedTracker is an independent research service that offers proprietary clinical assessments and patient-based revenue forecasts of developmental drugs within a comprehensive and intuitive drug information database. Clients from the pharmaceutical, biotech, and investment industries rely on BioMedTracker for its insight on the likelihood of approval, commercial potential, and future data and regulatory catalysts for drugs within the competitive landscape of every important disease and indication. Over the last several years, BioMedTracker has become the leader in providing objective information alongside subjective clinical assessments on pipeline drugs worldwide.
Bobbi Sue has a Bachelor of Science – Finance from Northern Arizona University, College of Business Administration.
_____________________________________________________________________________________________________________________________
|
| |
|
Dr. Patrick Romano Chief Operating Officer Deallus Group
_____________________________________________________________________________________________________________________________
|
|
|
|
Shelby Rosen Senior Strategic Planner Draftfcb HealthCare
Since joining Draftfcb HealthCare in 2006, Ms. Rosen has executed promotional and advertising campaigns as well as supported new client acquisitions. As Strategic Planner, monitoring competitive intelligence plays a critical role in ensuring strategic communications are differentiating.
Prior to joining Draftfcb, Ms. Rosen managed and executed custom-designed studies for healthcare clients at Hall and Partners Healthcare. Her therapeutic areas of expertise include HIV, dyslipidemia, urinary incontinence, vaccination, auto-immune diseases, hormone therapy, and many others. Shelby received her B.S.B.A, in Marketing and International Business from Washington University in St. Louis .
_____________________________________________________________________________________________________________________________
|
| |
|
Wayne Rosenkrans Distinguished Fellow, MIT Center for Biomedical Innovation VP Strategic Consulting, Fuld and Co. Program in Ethics and Systems Medicine, Georgetown University Chairman and President, Personalized Medicine Coalition Chief Applications Officer, SciTech Strategies
Wayne is a Distinguished Fellow at the Center for Biomedical Innovation at MIT working on healthcare strategy and policy issues related to science and medicine.&n bsp; He is also Chairman, President and a member of the board of directors of the Personalized Medicine Coalition, a Washington DC based organization working with government and other agencies on evolving healthcare policy for Personalized Healthcare, and Chief Applications Officer for SciTech Strategies focusing on scientific competency and capacity development for academia and industry. He is a former Director of External Relations for the Personalized Healthcare Team and Evidence-based Medicine (EBM) as part of External Medical Relations at AstraZeneca where he had responsibility for long-range external relations strategy and policy development. He is active on several strategy and advisory boards at different organizations including the C- Path Institute, Georgetown University, IBM, HP, and the Personalized Healthcare Initiative in the Secretary’s office at Health and Human Services. He has presented at numerous forums on aspects of personalized healthcare, evidence-based medicine, new development paradigms, and strategy development. He holds an S.B. in Biology from MIT, a Ph.D. in Cell and Molecular Biology from Boston Univ., and received post-doctoral training in Cancer and Radiation Biology at the Univ. of Rocheste r. Wayne lives in Malvern, PA, is married with two college-age children, and enjoys teaching martial arts (Tang Soo Do), restoring antique/classic Fords, and aviation history.
_____________________________________________________________________________________________________________________________
|
|
|
|
Birgit Rubensdoerffer Boehringer Ingelheim
Study of Chemistry / Master of Science of Chemistry (1989) Senior Consultant at SVP Business Consultants Germany (till 1997) Patent Analyst at Boehringer Ingelheim (till 2004) CTI Manager at Boehringer Ingelheim (ongoing)
_____________________________________________________________________________________________________________________________
|
|
|
|
Laura Ruth, Ph.D., Director, Healthcare Fuld & Company
Laura Ruth, Ph.D. is a Director with Fuld’s Pharmaceutical and Healthcare Practice. She received her Competitive Intelligence Professional (CIP™) Certificate in December 2008 and published a Competitive Intelligence ‘How-To’ guide featuring Fuld expertise with Kalorama Information in November 2008. While at Fuld she has investigated and evaluated a wide range of pharmaceutical, vaccine, managed care, and device competitive market issues, such as sales, marketing, regulatory, pipeline products, and clinical trials.
Prior to joining Fuld, Ms. Ruth was an independent medical, science, and technology writer and consultant covering a wide range of science, technology, business, policy, and regulatory topics. She provided a wide range of services to educational, biotechnology, journalism, and market research clients for six years following a nine-year career as a biological chemistry laboratory scientist, which included work at Lawrence Berkeley Laboratories and Syntex.
The market research reports were written for Business Communications Company, Inc., Cambridge Healthtech Advisors, Drug & Market Development, and Kalorama Information. Genetic & Engineering News reviewed two of the reports on DNA diagnostic technologies. In the fall of 2005, Ms. Ruth spoke as an invited speaker at the European Nutrigenomics Organization (NuGO) meeting in Mallorca about the report: ‘Nutrigenomics: Impacts on Markets, Diets, and Health.’ The National Academy of Sciences’ Nutrigenomics meeting in Washington, DC, in June 2006 featured the report as a current industry review.
As a scientific writer, Ms. Ruth created material for many academic and corporate organizations. Examples of the organizations include the National Academy of Sciences, Analytical Chemistry, EMBO Reports, Oncology News International, and Catalyst Oncology. Most recently she published ‘Bio or Bust?’, a review of biofuel environmental, economic, and policy issues for EMBO Reports.
Ms. Ruth holds a B.S. in chemistry from MIT and a Ph.D. in biological X-ray crystallography from the University of Pennsylvania. She set-up and executed an NIH interdisciplinary post-doc in biological X-ray crystallography and molecular diagnostics at UCLA and Cedars-Sinai Medical Center, where she was a member of three different labs. The projects included crystallization of alpha-L-iduronidase enzyme (Mucopolysaccharidosis I, Hurler Syndrome) and development of a DNA diagnostic chip. _____________________________________________________________________________________________________________________________
|
|
|
|
Mary Ann Sarao Sr. Director, Strategic Business Intelligence DSM Pharmaceuticals
Mary Ann Sarao is currently the Sr. Director Strategic Business Intelligence at DSM Pharmaceutical Products, headquartered in Parsippany, NJ. In Mary Ann's leadership position at DSM, she is building and executing Strategic Business Intelligence for three contract manufacturing business units: Biologics, APIs and Secondary Manufacturing. She is responsible for a team in both the US and Vienna.
A native of New Jersey, Mary Ann brings 25 years of global pharmaceutical industry experience. Prior to DSM , Mary Ann held positions of increasing responsibilities at Merck, Pfizer, J&J and Bristol-Myers Squibb in Strategic and Competitive Intelligence. Always interested in leveraging new technology, Mary Ann designed multiple intelligence networks within the Pharma Industry. As a Director of Business Intelligence within Pfizer’s Corporate Legal Department, Mary Ann had the unique opportunity to build an intelligence network to track counterfeit pharmaceutical products around the globe. During those four years at Pfizer, consumer health and safety was Mary Ann’s primary concern. As a result, she received in 2006 an Award from Law Technology News for the Most Innovative Use of Technology in a Legal Department.
Mary Ann is an innovative industry professionals who is dedicated to the creating a new paradigm shift in the Pharmaceutical Industry. A graduate of Seton Hall University in Nursing, Mary Ann pursued a business career and attained her Masters degree from Rutgers University. Mary Ann’s understanding of the complex healthcare environment, emerging markets, knowledge of biosimilars and intelligence gathering techniques significantly contributes to DSM's growth in the Life Sciences. _____________________________________________________________________________________________
|
|
|
|
Aaron Schacht Executive Director/COO - Global External R&D Eli Lilly
Aaron Schacht is Executive Director/COO for Global External R&D at Elil Lilly and Company. Aaron is an experienced and strategic executive leader and entrepreneur in the Pharmaceutical/Life Science Industry; and has expansive experience in Drug Discovery, Drug Development and Life Science & Information Technologies. Aaron brings a unique experience to new R&D models, having experienced both the large pharma and small, venture funded start- up environment. Among Aaron’s accomplishments in this space are:
1) Devised/implemented novel VC vehicles to fund surplus early stage assets 2) Architect of Lilly’s R&D FIPNet Strategy and R&D Productivity Strategy 3) Leader of Lilly’s R&D Portfolio Management 4) Leader of mission critical and transformational R&D and Corp IT systems 5) Created 4 novel spinout R&D ventures 6) Founder of Venture Backed Biopharmaceutical Company 7) Co-Inventor of the Innocentive Concept
Aaron joined Lilly in 1990 as a medicinal chemist, holds a BS is Chemistry from the University of Illinois at Urbana-Champaign ___________________________________________________________________________________________________________
|
| |
|
Indra Sethy-Coraci Principal Analyst Boehringer Ingelheim
_____________________________________________________________________________________________________________________________
|
|
|
|
C. David Seuss CEO Northern Light
C. David Seuss is the CEO of Northern Light. Based in Cambridge, Massachusetts, Northern Light provides strategic research portals to the largest, most research-driven, most innovative companies in the world. Clients include global organizations that are leaders in information technology, pharmaceuticals, telecommunications, finance, and other industries. On behalf of its clients, Northern Light annually aggregates and indexes over 25 million research documents from third-party research providers with a licensing value of over $2 billion. Northern Light’s own research focus is the automated analysis and discovery of meaning from large repositories of market intelligence and technology research. Mr. Seuss has been the CEO of Northern Light since its beginning in 1996. His prior experience includes founding Spinnaker Software, which he led from inception to publicly-traded company listed on NASDAQ. Before Spinnaker, Mr. Seuss was a manager and consultant for the Boston Consulting Group. He holds an MBA from the Harvard Business School and a bachelor of industrial engineering from Georgia Tech, and is a member of the board of advisors of the Tennenbaum Institute of Georgia Tech. _____________________________________________________________________________________________________________________________
|
|
|
|
Sanjiv Sharma Vice President of Commercial Affairs Nicox
Sanjiv Sharma has successful experience both at National and Global levels in Pharmaceutical Marketing, Sales Management, Strategic Planning, Market Access, and Government Affairs. He has a sound knowledge of pharmaceutical markets and healthcare systems in both North American and Asia. Currently, as a VP Commercial Affairs, He heads the commercial operations for NicOx SA and He is responsible for implementing a global commercial strategy for NicOx’ portfolio and defining and implementing the strategy for establishing sales and marketing operations in preparation for the launch of naproxcinod, the first compound in the CINOD class and the Company’s lead product for the treatment of the signs and symptoms of osteoarthritis. Sanjiv is also heads NicOx’s US operations and is a member of the Company’s Executive Committee. Before joining NicOx, He was head of Strategic Marketing & Business Analysis (SMBA) function for Biovail Pharmaceutical Inc, USA. In this role, he was responsible for new product commercialization and strategic life cycle management across five therapeutic areas with a special focus on Wellbutrin XL and Ultram ER franchise: marketing of the current legacy product portfolio.
Before joining Biovail, he worked for Sanofi-Aventis and its predecessor companies for 15 years. During these 15 years, he experienced the success of several companies’ key brands through various commercial roles, e.g. Cardizem, Lovenox, Altace, Texotare, Amaryl, Lantus and Exubera.
In the Global Marketing role in USA, He led several global cross-functional teams, in a matrix organization involving R&D, business development, brand teams for USA, Japan and EU. Actively involved or led several strategic endeavors, e.g., Roadmap for Aventis Diabetes leadership; Non injectable insulins strategy: North American Leadership Strategy; Aventis first Global Dynamic Diabetes Market Model for strategic planning and forecasting multiple opportunities, and was also involved in several major Business Development deals and partnerships.
At Aventis Canada, He was a member of the Management Committee (PMC) .Led three functional departments within commercial affairs and led or involved in five products launches.
For his contribution in building innovative healthcare solutions, he was awarded “ The Year 2000 Who’s Who in Healthcare” by Rogers Media, the largest healthcare publishing group in Canada. He holds MBA with Distinction from Richard Ivey School of Business, University of Western Ontario, Canada, and was designated as an Ivey Scholar for Scholastic Excellence.
_____________________________________________________________________________________________________________________________
|
|
|
|
Robert Siegmund Director Global Commercial Analysis Actelion
Dr. Robert Siegmund obtained a M. Sc. in Biochemistry from the University of Zurich, a Ph.D. in Genetics from the University of Vienna and a MBA from London Business School.
He started his career in the pharmaceutical industry doing basic research in cancer biology at the Institute of Molecular Pathology in Vienna, which belongs to the Boehringer Ingelheim Group. After MBA graduation Robert joined AMGEN where he worked in roles of increasing responsibility in the areas of market research and strategic planning, first in the German affiliate and then in the International headquarters. In 2004 Robert moved to the global headquarters of Roche to support the launch of a leading oncology product with market research, forecasting and competitive intelligence in his role as Business Analysis Manager.
Since 2009 Robert is Director, Global Commercial Analytics at Actelion Headquarters in Switzerland. Robert is leading a team generating insights by market research, competitive intelligence and business analytics. His team provides strategic advice and forward-looking decision intelligence to global strategic marketing, business operations and global business development.
_____________________________________________________________________________________________________________________________
|
| |
|
Peter Simpson Chairman Biogenerics Australia
_____________________________________________________________________________________________________________________________
|
| |
|
Kim Slocum Incoming President of HIMMS and former strategist at AstraZeneca KS Consulting
Kim Slocum is President of KDS Consulting, LLC, an organization devoted to helping health care organizations understand the environment in which they operate and assisting them in finding strategic, sustainable solutions to the business challenges they face. The company provides services to a growing list of clients including payers, providers, life sciences firms, information technology firms, trade associations, and health care industry advisory organizations.
Before founding KDS Consulting in July 2006, Mr. Slocum worked for more than thirty-three years as an employee of a variety of pharmaceutical, biotechnology and health care firms. Most recently he was Director of Strategic Planning and Business Development for AstraZeneca Pharmaceuticals where helped to lead the company’s effort to develop innovative tools to better understand and shape its external environment. Over his corporate career Mr. Slocum worked in a series of positions in sales, sales training, marketing, new product development, managed care marketing, disease management, health care consulting, strategic planning and externalization efforts.
In recent years, Mr. Slocum has become deeply involved with health care information technology. He is a Fellow Member of the Healthcare Information and Management Systems Society (HIMSS), a former member of the Society’s Board of Directors, a recipient of the Society’s 2005 Board Service Award, and a recipient of the July 2005 “Spirit of HIMSS” award. He also continues to be active in health policy issues and among other activities he is the Chair Elect of the Board of Trustees for the Texas Health Institute in Austin, Texas.
Mr. Slocum is a frequent speaker on issues related to the future of health care, the pharmaceutical industry, and the strategic importance of health care information technology. He participated in the 2002 “Health Leaders” Roundtable on the pharmaceutical industry. He has also given over numerous presentations to wide range of external audiences over the past several years, recently including, the Agency for Healthcare Research and Quality (AHRQ), the Deputy Commissioners of the Food and Drug Administration, the University of Mississippi School of Pharmacy, the Harvard University School of Public Health Policy, the European Pharmaceutical Marketing Research Association, the Pharmaceutical Marketing Research Group, the Society of Allied Chemical Manufacturers Association, the National Managed Health Care Congress, the Healthcare Information and Management Systems Society, the World Healthcare Congress, the Academy of Managed Care Pharmacy, the Western Medicaid Pharmacy Administrators’ Association, the National Lieutenant Governors’ Association, the National Governors’ Association, the Florida Association of Health Plans, US Senate staff, and members of various state legislatures.
In recent years, Mr. Slocum has also authored several pieces on health care. His first book, entitled “Consumer Directed Health Care, A 360 Degree View” published in July 2008 by CRC Press describes the history of US health insurance, factors that contribute to its higher cost relative to other countries, and the role consumers might be able to play in a transformed health care delivery system. His March 2007 article entitled “Trigger Points” was published in Pharmaceutical Executive and described a vision for the future of pharmaceutical industry sales forces. His March 2009 article entitled “Health Care— Rational or Rationed?” was published in Pharma Marketing News and described three alternate scenarios for the future of the biopharmaceutical industry.
Mr. Slocum earned his Bachelor’s Degree at the State University of New York at Geneseo and did his graduate studies in Business at Xavier University. He resides in West Chester, Pennsylvania.
_____________________________________________________________________________________________________________________________
|
|
|
|
Kim Szymanowski Competitive Intelligence Manager Ethicon, a Johnson & Johnson Company
Kim Szymanowski has worked at Ethicon, a Johnson & Johnson medical device company for the past 24 years. She has worked in most functional areas throughout the organization including: 12+ years in Suture, Needle, Packaging and Sterilization Manufacturing 5+ years in New Product Development 3+ years in Resource & Portfolio Management 1+ years in Strategic Planning 3 years in Competitive Intelligence (within Marketing)
Kim has helped build the Competitive Intelligence function and foundation over the past 3 years at Ethicon. This has included developing internal systems to help improve access and disseminate intelligence to the organization. Several of these systems have been highlighted as a Best Practice within J&J and are being leveraged across the sectors. With the medical device business being quite different from the pharmaceutical industry, data access and availability is extremely difficult to obtain. This has resulted in creative approaches to build competitive pipelines using a number of different sources available from public domains. The past three years have been an incredibly exciting time in the medical device Competitive Intelligence business - it’s been a tremendous learning curve for Kim.
Kim has a Bachelor’s of Science degree in Industrial Engineering and has been a member of SCIP for the past 2 years.
_____________________________________________________________________________________________________________________________
|
|
|
|
Michael D. Taylor, Ph.D. President & CEO Ensemble Discovery Corp.
Michael D. Taylor, Ph.D. - Dr. Taylor is currently President and CEO of Ensemble Discovery Corp. in Cambridge, MA. He is also a member of the Board of Directors of Cequent Pharmaceuticals. Dr. Taylor has been in the pharmaceutical industry for more than twenty years with extensive experience in drug discovery and development, licensing and business development, and managing R&D alliances with pharmaceutical and biotech partners. Prior to joining Ensemble Discovery in 2007, Dr. Taylor served as Senior Vice President for Pfizer¹s Global R&D division where he was responsible for global project and portfolio management. In other positions with Pfizer (and previously Warner-Lambert/Parke-Davis), Dr. Taylor led discovery, and early- and late-stage development projects across multiple therapeutic areas, including Lipitor® and Neurontin.® He has authored or coauthored 65 articles, reviews, and published abstracts and holds 6 patents. Dr. Taylor earned a Ph.D. in Medicinal Chemistry from the State University of New York at Buffalo and was awarded an NIH postdoctoral fellowship in natural products synthesis and structure elucidation at the University of Pennsylvania.
_____________________________________________________________________________________________________________________________
|
|
|
|
Jack Tsai Principal, Competitive and Technical Intelligence Genzyme
Jack is a Principal Intelligence Analyst in the Genzyme Transplant business unit. Jack drives the use of market intelligence and analytics – including epidemiology estimates, patient-based disease forecasts, product analogue models, and quantitative unmet need analysis – to facilitate better decisions across business and science portfolio projects. Additionally, he provides ad hoc analysis of global industry and market trends in both Science portfolio projects and business development initiatives.
_____________________________________________________________________________________________________________________________
|
|
|
|
Corina Turnes Global Practice Leader Healthcare Evalueserve
Corina Turnes is the Healthcare Practice Leader of Evalueserve. Evalueserve is a global knowledge solutions provider founded in the year 2000 offering research and analytics solutions with an emphasis on higher complexity processes. Evalueserve has now grown to 2,300 people located in global delivery centres in India, China, Chile and Romania.
Prior to joining Evalueserve Corina was a European Director with Pennside, a consulting business to the healthcare industry focusing on business intelligence and competitive analysis. Prior to this she worked with a-connect, where she prepared the foundation for the global life sciences practice and supported the building of a-connect’s presence in Asia out of the Hong Kong office. Corina also founded an independent consulting company focusing on the Healthcare industry. Corina started off her career at McKinsey & Co. where she has been working on strategic and operational topics. Corina received a Masters in sports science and physical education at the Swiss Federal Institute of Technology, Zurich.
Corina has worked on over a hundred projects within the Pharmaceuticals and Biotech sectors in many of the key therapeutic indications and has in-depth understanding of the organizational, strategic and tactical aspects associated with drug development and commercialisation.
Since 2004 Corina is an Associate Faculty Member in the Department for Strategic Management of the zfu International Business School, Switzerland.
_____________________________________________________________________________________________________________________________
|
| |
|
Rakesh Verma Director CIS Lifesciences
Rakesh stated out is career as a vet in India. In order to further understand disease processes and immune responses he gained an MSc in Immunology with a Distinction from the Royal Postgraduate Medical School, London and a Ph.D. in Immunology from Imperial College London in genetically engineering recombinant therapeutic antibody fragments for clinical oncology applications.
At CIS Life Sciences Rakesh is a Director and responsible for maximizing the insight gleaned from pre-clinical and clinical programs with a particular focus on Oncology, Immunology and biologics.
Prior to joining CIS Life Sciences, Rakesh had more than 12 years’ experience in the biopharmaceutical industry as a head of department at an oncology focused company, Antisoma, where he initiated, developed and drove forward concepts and ideas to development stage projects. He is the inventor on product-specific patent applications and has authored research articles, scientific reviews and book chapters. In addition, he has experience in writing regulatory and CMC documentations, submitting patent applications, reviewing business development opportunities, due diligence and licensing. Rakesh has made various presentations at international conferences, meetings and to collaborators and partners.
_____________________________________________________________________________________________________________________________
|
|
|
|
Sheila Walcoff Partner, McDermott Will & Emery LLP former Chief Counsel to Secretary Leavitt, HHS
Sheila D. Walcoff is a partner in the Washington DC office of the law firm of McDermott Will & Emery LLP and a member of the Firm’s Health Industry Advisory Group and co-leads the Life Sciences/Medical Products Government Strategies Team. Her clients include leading pharmaceutical and biotechnology companies, innovative diagnostic companies, policy associations and coalitions.
A recognized health policy expert, Ms. Walcoff focuses her practice on personalized medicine and related science and health policy, FDA regulatory, legislative and legal matters. Previously, Ms. Walcoff served as Counselor to the Secretary of the U.S. Department of Health and Human Services (HHS), Associate Commissioner for External Affairs at the Food and Drug Administration (FDA) and the health policy team leader/senior health policy advisor to a 2008 presidential campaign. She also has significant legislative strategy and advocacy experience and served as the majority counsel to the U.S. House of Representatives Armed Services Committee. Her ongoing pro bono work includes legislative and policy counsel to a national eating disorder association. Ms. Walcoff serves on the HHS Secretary’s Advisory Committee on Genetics, Health and Society (SACGHS), the Massachusetts Institute of Technology (MIT) Center for Biomedical Innovation (CBI) Strategy and Policy Council, and the Board of the Friends of the National Zoo (FONZ).
Outside of her law firm practice Ms. Walcoff is an entrepreneur and co-owns several veterinary hospitals. She earned her J.D. from the Georgetown University Law Center and resides in Maryland with her husband, Dr. Jeff Walcoff, their two young sons, and two Labradors.
_____________________________________________________________________________________________________________________________
|
|
|
|
Sue Ward Senior Director, Worldwide Competitive Intelligence Pfizer
Sue Ward is currently Senior Director of Worldwide Competitive Intelligence within Pfizer’s Corporate Strategic Planning group. Previously within Pfizer, Sue led the competitive intelligence team within Information & Knowledge Management. Prior to joining Pfizer, Sue worked in the UK as Associate Director of Competitive Analysis for SmithKline Beecham (SB) (now GSK). Other positions held by Sue within SB included managing a Clinical Information group and the Product Literature Information Service. Sue holds a BSc (Hons) in Biology from University College London and an MSc in Information Science from The City University, London .
_____________________________________________________________________________________________________________________________
|
|
|
|
Dr. Ben Weintraub Director of Research Wolters Kluwer Health
After completing his training in immunology and biochemistry, Dr. Weintraub began work as a financial analyst in 2000. Collaborating with Dr. Henderson, Dr. Weintraub co-founded BiotechTracker, an online tool for investors. In 2004, he became a licensed security analyst with Hibernia Southcoast Capital covering the biotechnology sector, and later performed the same role at Variant Research. In 2006, Dr. Weintraub joined Dr. Henderson and Dr. Zuckerman at Reuters Insight, providing analysis of drug development and trends in medicine to professional investors. Dr. Weintraub’s team moved to Wolters Kluwer in January 2009.
Prior to 2000, Dr. Weintraub was senior scientific editor for the biology research journals Cell and Molecular Cell. Dr. Weintraub performed biochemistry and immunology research at Stanford University and at the John Curtin School of Medical Research in Canberra , Australia . He earned his doctorate in Biology from the University of California , San Diego , and a bachelor of science in Life Science from the Massachusetts Institute of Technology. _____________________________________________________________________________________________________________________________
|
|
|
|
Thorsten Wichtendahl Senior Manager, Strategic & Competitive Intelligence Pfizer Australia
Thorsten has been working in the Competitive Intelligence space for over 10 years and currently leads the Strategic and Competitive Intelligence team at Pfizer Australia. His expertise is in delivering strategic insights and advancing senior managements understanding of their industry’s competitive environment. Besides Pharmaceuticals, he also has extensive experience in the Wealth Management, Financial Planning and Insurance sectors, focussing on strategic planning, competitive intelligence, customer analytics and sales reporting.
He has a MBA in International Management and Finance, a Master in Accounting and a Bachelor of Business in European Business and Marketing. He is a CPA and currently writes his PhD thesis in Strategic Management and Competitive Intelligence.
_____________________________________________________________________________________________________________________________
|
|
|
|
Friederike Wirtz-Brugger, Ph.D Associate Director, Scientific Competitive Intelligence Sanofi-Aventis
Twenty eight years experience in Pharmaceutical research both as a Research Scientist and Senior Manager of Scientific Competitive intelligence
Senior Manager, Scientific Competitive Intelligence (SCI) , Sanofi-Aventis, US and France (2003 - present)
- Providing and managing intelligence analyses of the competitive landscape for cardiovascular and
thrombosis indications as part of a global SCI group.
- Evaluation of competitor strategies, identification of trends and product licensing opportunities for
French managed company.
- Effective global communication of interpretation and recommendations based on competitive
analysis to the research community in US , France and Germany and global marketing and development project teams.
Senior Research Scientist, Aventis Pharma, US and Germany (until 2003)
- Managing and leading several early drug discovery and research project teams in the area of multiples sclerosis and inflammatory neurological
disease processes.
- Extensive knowledge in disease areasof CV, Thrombosis and CNS.
- Played a leadership role in Aventis / Millennium Collaboration as a representative on both target
identification and validation teams.
Education: Ph.D., Physiology and Neurobiology, UMDNJ (The University of Medicine and Dentistry of New Jersey) and Rutgers University, Graduate School, NJ, USA.
Diplom-Ingenieur, M.S. degree / Chemical and Biomedical Engineering, University Giessen, Germany.
____________________________________________________________________________________________________________________________
|
|
|
|
Richard Withers CEO Deallus
Richard is the CEO of the Dealllus Group. Following several years service as a military intelligence officer, Richard retired, went to Business School and started consulting to the Pharmaceutical Industry on intelligence matters.
Over his career he has facilitated over 100 strategic workshops such as War Games and Scenario Analysis events and has advised CI Managers and their Customers in R&D across to Marketing on what to expect from CI and how to derive maximum value from it.
_____________________________________________________________________________________________________________________________
|
|
|
|
Wendy Ye Principal Competitive Intelligence Specialist Medtronic Inc
Wendy Ye is a Principal Competitive Intelligence Specialist. She designed and implemented Competitive Intelligence program and process for Medtronic Neuromodulation. She leads competitive analysis and created tools, web site to support strategic planning and business decision. Before joining Medtronic in 2004, Wendy worked for Lucent Technologies as Sr. CI specialist and project manager in telecommunication field.
Wendy also worked for GCC, a Boston based consulting firm on medical device and telecom related patent litigation support, where she provided Japanese and US patent analysis and prior art search. Wendy started her career as a researcher and Biomedical Engineer at MIT, Division of Health Sciences and Technology, and Harvard VA Medical Center.
Wendy received her BS from Zhejiang University, China and MS from Tokyo Institute of Technology, Japan.
_____________________________________________________________________________________________________________________________
|
| |
|
|
|